Synergy Pharmaceuticals, Inc. [SGYP] Chairman & CEO to Ring The NASDAQ Stock Market Closing Bell
March 15 2012 - 10:00AM
ADVISORY, March 15, 2012 (GLOBE NEWSWIRE) --
What:
Synergy Pharmaceuticals, Inc. [SGYP], a biopharmaceutical
company focused on developing new treatments for GI disorders and
diseases, will visit the NASDAQ MarketSite in Times Square.
In honor of the occasion, Gabriele M. Cerrone, Chairman of the
Board, and Gary S. Jacob, CEO will ring the Closing Bell.
Where:
NASDAQ MarketSite – 4 Times Square – 43rd & Broadway –
Broadcast Studio
When:
Friday, March 16, 2012 – 3:45 p.m. to 4:00 p.m. ET
Contact: Bernard Denoyer (212)
297-0020 bdenoyer@synergypharma.com
NASDAQ MarketSite: Jen Knapp (212) 401-8916
Jennifer.knapp@nasdaqomx.com
Feed Information: Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Facebook and Twitter:
For multimedia features such as exclusive content, photo
postings, status updates and video of bell ceremonies please visit
our Facebook page at:
http://www.facebook.com/#!/NASDAQ.
For news tweets, please visit our Twitter page at:
http://twitter.com/nasdaqomx
Webcast:
A live webcast of the NASDAQ Closing Bell will be available
at:
http://www.nasdaq.com/about/marketsitetowervideo.asx or
http://social.nasdaqomx.com.
Photos:
To obtain a hi-resolution photograph of the Market Close, please
go to http://www.nasdaq.com/reference/marketsite_events.stm and
click on the market close of your choice.
About Synergy Pharma
[SGYP]:
Synergy is a biopharmaceutical company focused on the
development of new drugs to treat gastrointestinal disorders and
diseases. Synergy's proprietary drug candidate plecanatide is a
synthetic analog of the human gastrointestinal hormone uroguanylin,
and functions by activating the GC-C receptor on epithelial cells
of the GI tract. Synergy completed a Phase I study of plecanatide
in healthy volunteers and a Phase IIa clinical trial in patients to
treat chronic idiopathic constipation (CIC) patients. In October
2011, Synergy initiated dosing of patients in a major Phase II/III
clinical trial of plecanatide in CIC patients. Plecanatide is also
being developed to treat constipation-predominant irritable bowel
syndrome, with the first trial in IBS-C patients planned for 2012.
Synergy's second GC-C agonist SP-333 is currently in pre-clinical
development to treat inflammatory bowel diseases. More information
is available at http://www.synergypharma.com.
About NASDAQ OMX:
The NASDAQ OMX Group, Inc. is the world's largest exchange
company. It delivers trading, exchange technology and public
company services across six continents, with more than 3,500 listed
companies. NASDAQ OMX offers multiple capital raising solutions to
companies around the globe, including its U.S. listings market,
NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX first North, and
the U.S. 144A sector. The company offers trading across multiple
asset classes including equities, derivatives, debt, commodities,
structured products and exchange-traded funds. NASDAQ OMX
technology supports the operations of over 70 exchanges, clearing
organizations and central securities depositories in more than 50
countries. NASDAQ OMX Nordic and NASDAQ OMX Baltic are not
legal entities but describe the common offering from NASDAQ OMX
exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn,
Riga, and Vilnius. For more information about NASDAQ OMX, visit
http://www.nasdaqomx.com. *Please follow NASDAQ OMX on Facebook
(http://www.facebook.com/#!/NASDAQ) and Twitter
(http://www.twitter.com/nasdaqomx).
-NDAQA-
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)
Historical Stock Chart
From Jul 2023 to Jul 2024